-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In the blink of an eye, August 2022 has come quiet.
Entering August, institutional research is still ongoing, and the pharmaceutical field has become one of the focuses of institutional resear.
Recently, a number of institutions have released record sheets of investor relations activiti.
Among them, Jiudian Pharmaceutical released a record form of investor relations activities on August 1, stating that the company accepted 151 institutional research on August 1, 202 The types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, and securities compani.
, Sunshine private equity institutio.
Xintian Pharmaceutical released a record form of investor relations activities on August 1, stating that the company received investigations from 12 institutional units on July 29, 202 The types of institutions are fund companies, securities companies, and sunshine private equity institutio.
The common people released a record form of investor relations activities on AugustThe company accepted a survey of 18 institutions on July 31, 202 The types of institutions are QFII, insurance companies, others, fund companies, securities companies, and sunshine private equity institutio.
Jiudian Pharmaceutical stated in this institutional survey that in the first half of 2022, the company's leading product, Loxoprofen Sodium Gel Patch, maintained a relatively strong growth momentum due to its outstanding clinical effect and strong terminal consumer dema.
It has also entered a period of rapid grow.
In the first half of 2022, the company achieved operating income of 1,030,962,000 yuan, a year-on-year increase of 489%; net profit attributable to shareholders of listed companies was 129,767,200 yuan, a year-on-year increase of 102%; The profit was 123613 million yuan, a year-on-year increase of 21
In response to the investor's question about how much research and development expenses Jiudian Pharmaceutical plans to invest in 2022, Jiudian Pharmaceutical said that the company has always attached great importance to product research and developme.
, laying the foundation for steady and long-term developme.
In response to the company's follow-up major varieties, progress and market analysis, Jiudian Pharmaceutical said that most of the company's research and development efforts will focus on the research and development of transdermal drug delivery products, and the company is vigorously developing transdermal drug delivery preparations, including ge.
Patches, topical patches, systemic patches, gels and creams, e.
, have more than 15 varieties under development, and the proportion of generic drugs and improved new drugs is close, and the main indications are analgesia and geriatric diseas.
At the same time, the company also has innovative drug projects under development; in this process, the company is also actively developing APIs and excipients related to topical preparations to solve the problem of key equipment and key excipients stuck in the neck of topical preparatio.
In answering questions from investors, Xintian Pharmaceutical stated that the overall development of the company is a continuous strategic layout and implementati.
As early as 2018, the company has implemented a series of product market strategic layouts in combination with the company's product lines, market channels, product markets and future expectations, including consolidating the construction of original channels, increasing the output of clinical sales channel markets, and consolidating hospita.
Coverage, increase output in sinking markets,e.
Xintian Pharmaceutical stated that it has completed the clinical phase III research of 3 new traditional Chinese medicine drugs, and is in the preparation period for the production of new drug projec.
Combined with the current research and development progress, it is basically in line with the previously expected production reporting time cyc.
Xintian Pharmaceutical said that for the company, formula granules and classic prescriptions are new growth points of future long-term strategy, and they are also an important part of the company's future development strate.
It is expected to have a positive impact on the company's development in the futu.
Among them, for the formula granule project, Xintian Pharmaceutical now has 445 varieties of Guizhou provincial standard, and has completed more than 100 varieties of national standard registrati.
In terms of research and development of classic prescriptions, Xintian Pharmaceutical currently has 7 varieties covering gynecology, pediatrics, respiratory and chronic diseases in the research and development pipeline, and plans to apply for marketing authorization after the relevant departments release the key information of the corresponding prescriptio.
In answering questions from investors, the common people said that the company mainly improves the quality of store operations from four aspec.
Through efficient organizational reform, implement a flat organization and a centralized management model to improve the communication and execution efficiency of the group's decision-maki.
Pay attention to the improvement of store operation fundamentals and enhance customer consumption experien.
Carry out salary reform for front-line employees and the use of digital tools such as salary calculators to increase employee income and improve the stability of front-line employe.
Fourth, realize refined operations through digitization and improve operational quality and efficien.
At the same time, it provides customers with more personalized and professional medication consultation and health management services through digital empowerme.
In this institutional survey, the common people said that the company has established a subsidiary to operate the franchise business independently since 201All along, the company's franchise business follows the "quasi-direct" management model, and implements "unified brand identity, unified management system, unified information system, unified personnel training, unified procurement and distribution, unified financial management, and unified pharmacy service standards" for franchise stor.
"Seven unified" high-standard management, delivery of goods, and strict regulation of store operatio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Entering August, institutional research is still ongoing, and the pharmaceutical field has become one of the focuses of institutional resear.
Recently, a number of institutions have released record sheets of investor relations activiti.
Among them, Jiudian Pharmaceutical released a record form of investor relations activities on August 1, stating that the company accepted 151 institutional research on August 1, 202 The types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, and securities compani.
, Sunshine private equity institutio.
Xintian Pharmaceutical released a record form of investor relations activities on August 1, stating that the company received investigations from 12 institutional units on July 29, 202 The types of institutions are fund companies, securities companies, and sunshine private equity institutio.
The common people released a record form of investor relations activities on AugustThe company accepted a survey of 18 institutions on July 31, 202 The types of institutions are QFII, insurance companies, others, fund companies, securities companies, and sunshine private equity institutio.
Jiudian Pharmaceutical stated in this institutional survey that in the first half of 2022, the company's leading product, Loxoprofen Sodium Gel Patch, maintained a relatively strong growth momentum due to its outstanding clinical effect and strong terminal consumer dema.
It has also entered a period of rapid grow.
In the first half of 2022, the company achieved operating income of 1,030,962,000 yuan, a year-on-year increase of 489%; net profit attributable to shareholders of listed companies was 129,767,200 yuan, a year-on-year increase of 102%; The profit was 123613 million yuan, a year-on-year increase of 21
In response to the investor's question about how much research and development expenses Jiudian Pharmaceutical plans to invest in 2022, Jiudian Pharmaceutical said that the company has always attached great importance to product research and developme.
, laying the foundation for steady and long-term developme.
In response to the company's follow-up major varieties, progress and market analysis, Jiudian Pharmaceutical said that most of the company's research and development efforts will focus on the research and development of transdermal drug delivery products, and the company is vigorously developing transdermal drug delivery preparations, including ge.
Patches, topical patches, systemic patches, gels and creams, e.
, have more than 15 varieties under development, and the proportion of generic drugs and improved new drugs is close, and the main indications are analgesia and geriatric diseas.
At the same time, the company also has innovative drug projects under development; in this process, the company is also actively developing APIs and excipients related to topical preparations to solve the problem of key equipment and key excipients stuck in the neck of topical preparatio.
In answering questions from investors, Xintian Pharmaceutical stated that the overall development of the company is a continuous strategic layout and implementati.
As early as 2018, the company has implemented a series of product market strategic layouts in combination with the company's product lines, market channels, product markets and future expectations, including consolidating the construction of original channels, increasing the output of clinical sales channel markets, and consolidating hospita.
Coverage, increase output in sinking markets,e.
Xintian Pharmaceutical stated that it has completed the clinical phase III research of 3 new traditional Chinese medicine drugs, and is in the preparation period for the production of new drug projec.
Combined with the current research and development progress, it is basically in line with the previously expected production reporting time cyc.
Xintian Pharmaceutical said that for the company, formula granules and classic prescriptions are new growth points of future long-term strategy, and they are also an important part of the company's future development strate.
It is expected to have a positive impact on the company's development in the futu.
Among them, for the formula granule project, Xintian Pharmaceutical now has 445 varieties of Guizhou provincial standard, and has completed more than 100 varieties of national standard registrati.
In terms of research and development of classic prescriptions, Xintian Pharmaceutical currently has 7 varieties covering gynecology, pediatrics, respiratory and chronic diseases in the research and development pipeline, and plans to apply for marketing authorization after the relevant departments release the key information of the corresponding prescriptio.
In answering questions from investors, the common people said that the company mainly improves the quality of store operations from four aspec.
Through efficient organizational reform, implement a flat organization and a centralized management model to improve the communication and execution efficiency of the group's decision-maki.
Pay attention to the improvement of store operation fundamentals and enhance customer consumption experien.
Carry out salary reform for front-line employees and the use of digital tools such as salary calculators to increase employee income and improve the stability of front-line employe.
Fourth, realize refined operations through digitization and improve operational quality and efficien.
At the same time, it provides customers with more personalized and professional medication consultation and health management services through digital empowerme.
In this institutional survey, the common people said that the company has established a subsidiary to operate the franchise business independently since 201All along, the company's franchise business follows the "quasi-direct" management model, and implements "unified brand identity, unified management system, unified information system, unified personnel training, unified procurement and distribution, unified financial management, and unified pharmacy service standards" for franchise stor.
"Seven unified" high-standard management, delivery of goods, and strict regulation of store operatio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
